Advertisement

Advertisement

CCCC Stock Latest News

C4 Therapeutics Reports New Cemsidomide Myeloma Data

Company AnnouncementsC4 Therapeutics Reports New Cemsidomide Myeloma Data

C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide

PremiumThe Fly

C4 Therapeutics presents biomarker data from Phase 1 trial of cemsidomide

6d ago

C4 Therapeutics reports Q2 EPS (18c), consensus (23c)

PremiumThe Fly

C4 Therapeutics reports Q2 EPS (18c), consensus (23c)

2M ago

CCCC Upcoming Earnings Report: What to Expect?

PremiumPre-Earnings

CCCC Upcoming Earnings Report: What to Expect?

2M ago

C4 Therapeutics Shareholders Back Directors, Pay and Auditors

PremiumCompany Announcements

C4 Therapeutics Shareholders Back Directors, Pay and Auditors

3M ago

C4 Therapeutics presents further analysis from cemsidomide trial

PremiumThe FlyC4 Therapeutics presents further analysis from cemsidomide trial

4M ago

C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress

Company Announcements

C4 Therapeutics Highlights Cemsidomide Strategy and Trial Progress

4M ago

C4 Therapeutics jumps after Bristol Myers myeloma data

The Fly

C4 Therapeutics jumps after Bristol Myers myeloma data

4M ago

C4 Therapeutics Realigns Finance Leadership After Officer Departure

PremiumCompany Announcements

C4 Therapeutics Realigns Finance Leadership After Officer Departure

5M ago

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

PremiumThe Fly

C4 Therapeutics reports Q1 EPS (20c), consensus (26c)

5M ago

C4 Therapeutics Reports Q1 Results and Clinical Advancements

PremiumCompany Announcements

C4 Therapeutics Reports Q1 Results and Clinical Advancements

5M ago

Is CCCC a Buy, Before Earnings?

PremiumPre-Earnings

Is CCCC a Buy, Before Earnings?

5M ago

C4 Therapeutics Expands Roche Collaboration with New DAC Deal

PremiumCompany AnnouncementsC4 Therapeutics Expands Roche Collaboration with New DAC Deal

6M ago

C4 Therapeutics expands long-term partnership with Roche

The Fly

C4 Therapeutics expands long-term partnership with Roche

6M ago

C4 Therapeutics doses first patient in cemsidomide trial

The Fly

C4 Therapeutics doses first patient in cemsidomide trial

6M ago

C4 Therapeutics price target raised to $7 from $5 at Barclays

PremiumThe Fly

C4 Therapeutics price target raised to $7 from $5 at Barclays

7M ago

C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating

PremiumRatings

C4 Therapeutics: Cemsidomide’s Best-in-Class CELMoD Potential and De‑Risking Clinical Momentum Support Buy Rating

7M ago

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

PremiumThe Fly

C4 Therapeutics reports Q4 EPS (18c), consensus (34c)

7M ago

C4 Therapeutics price target raised to $30 from $20 at Brookline

PremiumThe Fly

C4 Therapeutics price target raised to $30 from $20 at Brookline

7M ago

C4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

PremiumThe FlyC4 Therapeutics announces first patient dosed in Phase 2 MOMENTUM trial

7M ago

CCCC Upcoming Earnings Report: What to Expect?

Pre-Earnings

CCCC Upcoming Earnings Report: What to Expect?

8M ago

C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors

Company Announcements

C4 Therapeutics’ Phase 2 Myeloma Trial Moves Forward, Setting Up a Key Catalyst for CCCC Investors

9M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >